2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 20:41, 2 December 2023
, 2 December 2023no edit summary
No edit summary |
|||
| Line 103: | Line 103: | ||
While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | ||
* Taking 800 mg NMN pre day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels. | * Taking 800 mg NMN pre day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | ||
== Controversy about NMN as Direct Precursor == | == Controversy about NMN as Direct Precursor == | ||
| Line 143: | Line 143: | ||
* '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women{{pmid|33888596}} | * '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women{{pmid|33888596}} | ||
* '''Telomere''': increased telomere length{{pmid|34912838}} | * '''Telomere''': increased telomere length{{pmid|34912838}} | ||
* Hypertension: {{pmid|37718359}} | |||
|} | |} | ||
| Line 342: | Line 343: | ||
|- | |- | ||
|{{pmid text|36443648}} | |{{pmid text|36443648}} | ||
| | |||
| | |||
| | |||
|- | |||
|{{pmid_text|37718359}} | |||
* [https://www.nmn.com/news/nmn-lowers-blood-pressure-in-patients-with-hypertension-latest-human-trial NMN.com article] | *[https://www.nmn.com/news/nmn-lowers-blood-pressure-in-patients-with-hypertension-latest-human-trial NMN.com article] | ||
|6 weeks, lifestyle modifications | |6 weeks, lifestyle modifications | ||
* no NMN (n=10) | * no NMN (n=10) | ||
* 800 mg/day (n=9) | * 800 mg/day (n=9) | ||
| | | | ||
* 19 mild hypertensive adults | * 19 mild hypertensive adults | ||